Overview

CTS-1027 in Interferon-Naive Hepatitis C Patients

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.

Phase:

Phase 2

Details

Lead Sponsor:

Conatus Pharmaceuticals Inc.

Treatments:

Interferons
Ribavirin